Skip to content

Treatment of postherpetic neuralgia with serratus anterior plane block combined with erector spinalis plane block

The effect of serratus anterior plane block combined with erector spinalis plane block / thoracic paraspinal nerve block in the treatment of postherpetic neuralgia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037929
Enrollment
Unknown
Registered
2020-09-04
Start date
2020-09-07
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

group SE:serratus anterior plane block combined with erector spinae plane block
group P:thoracic paravertebral nerve block

Sponsors

Department of Anesthesiology, the First Affiliated Hospital of USTC,Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The subjects volunteered and signed the informed consent of the trial; 2. Patients aged 18 or more and less than 80 years, regardless of gender. 3. Patients with chronic herpes zoster neuralgia, and the pain site is located in the chest and abdomen; 4. Patients with moderate or severe pain but poor effect, vas > 4; 5. Patients who can objectively describe symptoms and actively cooperate.

Exclusion criteria

Exclusion criteria: 1. The patient had postherpetic neuralgia in other parts except chest and abdomen; 2. Patients with severe coagulation dysfunction; 3. Patients with severe heart, lung, liver and kidney dysfunction; 4. Patients who took other analgesics (including non steroidal anti-inflammatory drugs and opioids) in addition to the study protocol during the observation period; 5. Patients who have used drugs for the treatment of postherpetic neuralgia or used glucocorticoids and immunosuppressants within one week before enrollment; 6. Patients with local or systemic infection by puncture; 7. Patients with diabetes history > 5 years and blood glucose control not reaching the normal value (fasting blood glucose > 8 mmol / L, 2 h postprandial blood glucose > 10 mmol / L); 8. Patients who are allergic to known ingredients of the test drug; 9. Non lactating and pregnant women.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;Quality of Sleep, QS;

Secondary

MeasureTime frame
Total dosage of tramadol sustained release tablets;adverse reaction;

Countries

China

Contacts

Public ContactHai Gu

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China (USTC)

gqc1022@163.com+86 18605518936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026